Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that Zami Aberman, Chairman, President and CEO, has been invited by the Equity Forum in Stuttgart, Germany to present updates on the Company's corporate development in Germany and its Phase I clinical trials using the Company’s placental-derived stem cell product, PLX-PAD. Mr. Aberman will also discuss the arrangements with Charité – Universitätsmedizin Berlin and Franziskus-Krankenhaus Hospital for the upcoming Critical Limb Ischemia (CLI) clinical trials in Germany. The presentation, which is organized by the Deutsche Börse and the KfW SME Bank, will be held on April 29, 2009.

“Pluristem has established long term scientific collaborations with outstanding German institutions such as the Charité – Universitätsmedizin Berlin and the Fraunhofer Institute for Immunology and Cell Therapy in Liepzig,” stated Zami Aberman, Chairman, President and CEO of Pluristem. “We look forward to presenting our clinical trial’s progress, as well as the Company's future business plans, to the investment community at the Stuttgart Equity Forum.”

About the German Equity Forum

The German Equity Forum is one of the largest capital market conferences in Europe. The conference is organized by the Deutsche Börse and the KfW SME Bankengruppe. The Deutsche Börse is one of the world’s leading exchange organizations, which provides investors, financial institutions and companies access to global capital markets, while KfW Bankengruppe gives impetus to economic, social and ecological development worldwide and is a promotional bank under the ownership of the Federal Republic and the Länder (federal states).

About Pluristem